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Vaccination is considered the most effective strategy for controlling tuberculosis (TB).
The existing vaccine, the Bacille Calmette-Guérin (BCG), although partially protective,
has a number of limitations. Therefore, there is a need for developing new TB vaccines
and several strategies are currently exploited including the use of viral and bacterial
delivery vectors. We have previously shown that Lactobacillus plantarum (Lp) producing
Ag85B and ESAT-6 antigens fused to a dendritic cell-targeting peptide (referred to as
Lp_DC) induced specific immune responses in mice. Here, we analyzed the ability of
two Lp-based vaccines, Lp_DC and Lp_HBD (in which the DC-binding peptide was
replaced by an HBD-domain directing the antigen to non-phagocytic cells) to activate
antigen-presenting cells, induce specific immunity and protect mice fromMycobacterium
tuberculosis infection. We tested two strategies: (i) Lp as BCG boosting vaccine (a
heterologous regimen comprising parenteral BCG immunization followed by intranasal
Lp boost), and (ii) Lp as primary vaccine (a homologous regimen including subcutaneous
priming followed by intranasal boost). The results showed that both Lp constructs
applied as a BCG boost induced specific cellular immunity, manifested in T cell
proliferation, antigen-specific IFN-γ responses and multifunctional T cells phenotypes.
More importantly, intranasal boost with Lp_DC or Lp_HBD enhanced protection offered
by BCG, as shown by reduced M. tuberculosis counts in lungs. These findings suggest
that Lp constructs could be developed as a potential mucosal vaccine platform against
mycobacterial infections.
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INTRODUCTION
Tuberculosis (TB) continues to be one of themost deadly diseases
in the world and has been designated as a global public health
emergency by theWorld Health Organization (WHO) since 1993
(1). The WHO Global tuberculosis report of 2018 recounted
6.4 million new cases of TB in 2017 and the highest numbers
of incidents were recorded in India, Indonesia and Nigeria (2).
BCG, the only existing licensed TB vaccine, has been used in
humans worldwide for nearly ten decades, although its efficacy
remains debated (3–5). While BCG prevents TB infections in
infants and children, the protection against pulmonary TB in
adults and adolescents is incomplete and inconsistent (6, 7).
Moreover, the BCG vaccine, though generally safe and well-
tolerated, is inapplicable to immunosuppressed people, such
as HIV-infected subjects, due to adverse effects and a risk of
disseminated BCG infection (8–10). The questionable efficacy of
BCG, together with increasing numbers of drug resistant strains
ofMycobacterium tuberculosis, the causative agent of TB, raise an
urgent need for developing a new effective vaccine that could halt
the spread of TB.
Mycobacterium tuberculosis is a pathogen of the respiratory
tract entering the body through mucosal tissue. Multiple studies
have demonstrated that mucosal immunization to the airway
(including intranasal or aerosol delivery), which mimics natural
infections, is more protective than use of parenteral vaccines. It
has been shown that mucosal delivery enhances the generation of
tissue resident memory T cells that may inhibit the early phases
of mycobacterial infection (11, 12).
A number of novel TB vaccine candidates are being
considered and they include the following types: (i) prophylactic
priming vaccines that may substitute BCG, (ii) prophylactic BCG
boosting vaccines, and (iii) therapeutic vaccines for exposed
individuals at risk of remission (4, 9). Currently, at least 13
vaccine candidates against TB are being tested in clinical trials
(6, 9) including whole cell vaccines and subunit vaccines.
Today, viral vectors are the only heterologous vehicles
for TB vaccines that have reached clinical trials. Vaccine
candidates based on replication-deficient viruses include: (i)
modified Vaccinia Ankara virus [MVA85A; (13, 14)], (ii)
human adenovirus 5 [Ad5Ag85A; (15)], (iii) chimpanzee
adenovirus [ChAdOx1.85A, (13)] or (iv) human influenza
virus [TB/FLU-04L, (6, 9, 16)]. All of these carry antigen
85A, which is an enzyme involved in cell wall synthesis of
M. tuberculosis (17). Besides viruses, bacteria-based heterologous
vectors are attractive carriers for a potential new TB vaccine
and studies in animal models have already shown encouraging
results both for attenuated pathogens and non-pathogenic
bacteria. For example, among pathogenic bacteria, attenuated
L. monocytogenes expressing M. tuberculosis antigens enhanced
protection against aerosolized M. tuberculosis in BCG-primed
mice (18, 19). Similarly, Salmonella typhimurium secreting a
mycobacterial antigen reduced numbers of tubercle bacilli in the
lungs of infectedmice (20, 21).While the utilization of attenuated
pathogens in the TB vaccine field seems promising, this strategy
poses a risk of virulence reversion, and therefore, there is an
increasing interest in studying safer alternatives, such as lactic
acid bacteria (LAB) or Bacillus subtilis spores. Interestingly,
recombinant B. subtilis spores expressing TB antigens, were
shown to be immunogenic (22), and more importantly, to induce
protective immunity against aerosolized mycobacterial bacilli in
a murine model (3, 23).
LAB are non-sporulating Gram-positive bacteria that, due to
their safe status and well-developed genetic engineering toolbox,
have been widely explored as vectors for delivery of prophylactic
and therapeutic molecules for almost three decades (24–27). In
vaccine development, Lactococcus lactis and Lactobacillus spp.
are the most intensively explored, and Lactobacillus planatrum
(25) and L. lactis (28–31) have been explored as carriers for DNA-
(29–31) or protein-based (25, 28) TB vaccines. Although L. lactis
remains the most utilized model LAB, L. plantarum (Lp) seems
to be a more advantageous vaccine candidate due to its known
immunomodulatory effects and adjuvant properties (32–37). In
a recent study, we have shown that recombinant Lp producing
a surface-anchored version of the M. tuberculosis Ag85B-
ESAT-6 fusion protein inducedMycobacterium-specific immune
responses when applied intranasally or orally in mice (25). The
present study builds on these encouraging preliminary data in
three ways: (1) construction of an alternative Lactobacillus-based
vaccine strain, (2) in-depth and comparative analysis of induced
immune responses, using a variety of experimental set-ups and,
most importantly, and (3) assessment of the protective efficacy of
the two vaccine candidates in an aerosolized low-dose TB model,
using pathogenic M. tuberculosis. These experiments not only
provide a first glimpse of the true potential of Lactobacillus-based
vaccines in combatting TB, but also allow an evaluation of the
extent to which immune responses observed in in vitro assays
correlate with the protective potential of the vaccine candidate.
Notably, protective efficacy of Lactobacillus-based TB vaccine
candidates has not been reported previously.
We describe two candidates for a subunit vaccine against
TB, based on Lp strains expressing a fusion of the Ag85B
and ESAT-6 mycobacterial antigens, referred to as AgE6. AgE6
was expressed on the bacterial surface using an N-terminal
lipoprotein anchor (25, 38) and a specific targeting molecule was
fused to the antigen: a DC-binding peptide targeting bacteria
to dendritic cells (construct Lp_DC) or a heparin binding
domain (HBD) of mycobacterial heparin binding hemagglutinin
(HBHA) that promotes binding to epithelial cells (construct
Lp_HBD). The recombinant strains were subjected to in vitro
phenotyping, followed by studies in mice to evaluate their
protective potential against aerosolized M. tuberculosis. The
study included two prime-boost immunization strategies: (i) a
heterologous vaccination regimen where Lp-based vaccines were
applied as a BCG booster, and (ii) homologous vaccination with
Lp_DC or Lp_HBD.
MATERIALS AND METHODS
Bacterial Strains, Plasmids, and Growth
Conditions
The bacterial strains and plasmids used in this study are listed
in Table 1. Lactobacillus plantarum constructs were cultured in
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TABLE 1 | Plasmids and strains used in this study.
Strain or plasmid Description References
PLASMIDS
pUC-AgE6 Ampr; pUC57 vector with synthetic
ag85besat6 gene
Genescript
pLp_1261AgE6-DC Eryr; pLp_1261AgE6 (25) derivative, encoding
the AgE6 antigen with a DC-binding peptide
fused to its C-terminus
(25)
pEV Eryr; control plasmid (“empty vector”) (38)
pLp_1261AgE6-
HBD
Eryr; pLp_1261AgE6-DC (25) derivative,
encoding the AgE6 antigen with a
heparin-binding domain (HBD) of HBHA fused
to its C-terminus
This study
STRAINS
L. plantarum
WCFS1
Host strain (39)
E. coli TOP10 Host strain Invitrogen
Lp_DC Lp_1261AgE6-DC; L. plantarum WCFS1
harboring pLp_1261AgE6-DC; using an
N-terminal covalent lipoprotein anchor for
surface display of the AgE6 antigen fused to
DC-targeting peptide
(25)
Lp_HBD L. plantarum WCFS1 harboring
pLp_1261AgE6-HBD; using an N-terminal
covalent lipoprotein anchor for surface display
of the AgE6 antigen fused to HBD fragment
This study
Lp_Ev L. plantarum WCFS1 carrying pEv (empty
vector); used as a negative control strain
(38)
BCG Bacillus Calmette-Guérin Pasteur strain
M. tuberculosis
H37Rv
Laboratory strain
MRS broth (Oxoid Ltd.) at 37◦Cwithout shaking. Escherichia coli
TOP10 cells (Invitrogen) were grown in Brain Heart Infusion
(BHI, Oxoid) broth at 37◦C with shaking. Erythromycin was
added to a final concentration of 10µg/ml for L. plantarum.
For E. coli final concentrations of erythromycin and ampicillin
were 200µg/ml and 100µg/ml, respectively. Bacillus Calmette-
Guérin Pasteur (BCG) and M. tuberculosis strain H37Rv were
cultivated in 7H10 broth (Becton Dickinson) at 37◦C. Liquid
7H10 was supplemented with ADC (Becton Dickinson), 0.05%
Tween-80 and Selectab (Mast Diagnostics). Solid 7H11 medium
was supplemented with OADC (Becton Dickinson), glycerol and
Selectab (Mast Diagnostics). Liquid medium was solidified by
adding 1.5% (w/v) agar.
DNA Manipulations and Plasmid
Construction
The basic outline of the constructed expression vectors is shown
in Figure 1. The fusion protein comprising the antigens Ag85B
and ESAT-6 of M. tuberculosis, and referred to as AgE6, was
designed as described previously (25). Lp_DC harbors the
pLp_1261AgE6-DC plasmid that was constructed for inducible
expression of the AgE6 antigen fused to DC-targeting peptide
(40, 41) and anchored to the bacterial surface via the Lp_1261
lipoprotein anchor, as described in a previous study (25). In
order to engineer Lp_HBD construct, the lp1261age6hbd gene
fragment was designed such as to fuse a 147 bp fragment
encoding the heparin-binding domain (referred here to as
HBD) from M. tuberculosis heparin-binding hemagglutinin
(HBHA; GenBank: AAC26052.1) to the C-terminal end of
AgE6. Three-amino acid linker, encoding Gly-Thr-Ala and
containing a KpnI restriction site, was introduced between
AgE6 and HBD. NdeI and HindIII restriction sites were
introduced upstream and downstream the lp1261age6hbha
gene fragment, respectively. Such designed lp1261age6hbha
DNA fragment was codon optimized for expression in
L. plantarum, synthesized at Genscript (Piscataway), and
cloned into a pUC57 plasmid, yielding pUC-HBD. The
pUC -HBD plasmid was digested by NdeI and HindIII. The
resulting 1560 bp Lp_1261-AgE6-HBD-encoding fragment was
cloned into NdeI/HindIII digested pLp_1261AgE6-DC (25),
yielding pLp_1261AgE6-HBD. The resulting plasmid was first
transformed into E. coli TOP10. Positive clones were screened
by PCR and restriction enzyme digestion after which the PCR-
amplified fragments were verified by sequencing using primers
SekF (GGCTTTTATAATATGAGATAATGCCGAC) and
SekR (CCTTATGGGATTTATCTTCCTTATTCTC). Plasmid
pLp_1261AgE6-HBHA was purified using PureYieldTM Plasmid
Miniprep System (Promega Corporation) and electroporated
into L. plantarum cells according to Aukrust et al. (42), yielding
Lp_HBD construct.
Preparation of L. plantarum Constructs
The expression of recombinant protein was induced and
bacterial cells were harvested 3 h after induction as described
elsewhere (25, 43). Recombinant bacteria were inactivated by
UV-irradiation for 1 h and the successful inactivation was
confirmed. Pellets of inactivated bacteria were stored at −80◦C
until use. In order to determine the number of CFU, freshly
harvested bacterial cells were cultivated on solid MRS medium
supplemented with antibiotics for 48 h and the colonies were
counted. The numbers of inactivated bacteria were verified after
storage at −80◦C by counting in a Buerker counting chamber
(Paul Marienfeld GmbH & Co. KG).
Growing of Mycobacterium Strains
Bacillus Calmette-Guérin Pasteur and M. tuberculosis were
grown to log phase at 37◦C in complete liquid 7H10 broth,
harvested and cryopreserved in liquid nitrogen until use. Freshly
harvested mycobacterial cells were cultivated on complete 7H11
agar plates for 3-4 weeks and the CFU were determined.
Western Blot Analysis
To analyze expression of recombinant fusion antigen in
L. plantarum, cells from a 50mL culture were harvested 3 h after
induction (25, 43) and resuspended in 500 µL PBS. Bacterial
protein extracts were prepared by disruption in FastPrep tubes
containing 1.5 g of glass beads (size ≤ 106µm; Sigma-Aldrich),
using a FastPrep R© FP120 Cell Disrupter with a shaking speed of
6.5 m/s for 45 s. After 5min incubation on ice the shaking process
was repeated. The glass beads were removed by sedimentation
and the protein extracts were transferred to a new tube. Proteins
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FIGURE 1 | Schematic overview of the surface-anchored recombinant AgE6 fusion antigen. The N-terminal end of the recombinant AgE6 hybrid antigen was fused to
the Lp_1261 lipoprotein anchor which attaches the protein to the cell membrane. Specific targeting peptides, here referred to as DC (A) or HBD (B), were fused to the
C-terminal end (i.e., the ESAT-6 side) of the AgE6 fusion antigen and thus form the most exposed part of the surface-anchored antigen. The DC-peptide
targets dendritic cells, whereas the HBD fragment targets bacteria to epithelial cells.
were separated by SDS-polyacrylamide gel electrophoresis using
10% Mini-Protean TGX Precast gels (BioRad) and transferred
to a nitrocellulose membrane using the iBlotTM Dry Blotting
System (Invitrogen). The proteins were detected using the
SNAP i.d. R© 2.0 Protein Detection System (Merck) using a
specific monoclonal mouse anti-ESAT-6 antibody (Abcam)
diluted 1:15000 and, subsequently, a polyclonal HRP-conjugated
rabbit anti-mouse IgG (DAKO), diluted 1:7500. Proteins were
visualized using the SuperSignalTM West Pico Chemiluminescent
Substrate (Termo Fisher Scientific) and signals were documented
using an Azure c400 system and AzureSpot Analysis Software
(Azure Biosystems), following the manufacturer’s instructions.
Flow Cytometry and Indirect
Immunofluorescence Microscopy of L.
plantarum Expressing Recombinant AgE6
Antigen
Surface display of recombinant AgE6 was analyzed in UV-
inactivated L. plantarum cells. Approximately 1 × 109 bacterial
cells were probed with monoclonal mouse anti-ESAT-6
antibody, followed by incubation with polyclonal rabbit FITC-
conjugated anti-mouse antibody, as described previously
(25). Stained bacterial cells were analyzed by flow cytometry
using a MACSQuant analyzer (Miltenyi Biotec), following the
manufacturer’s instructions. For indirect immunofluorescence
microscopy, bacteria were visualized on a Zeiss Axio Observer.z1
microscope (Zeiss) and the fluorescence was acquired by EX
450-490 nm and EM 500-590 nm (EX, excitation; EM, emission).
Isolation of Human Dendritic Cells (DCs)
Human peripheral blood mononuclear cells were isolated and
handled according to institutional ethical guidelines (Østfold
Hospital Trust, Norway), as described elsewhere (25). Briefly,
cells were isolated by density gradient centrifugation for 25min
at 1,500 × g using Lymphoprep TM (Axis-Shield Diagnostics
Ltd.) at room temperature and washed four times with PBS
to remove the platelets. CD14+ cells were separated on an
LS column (Miltenyi Biotec) using human CD14 MicroBeads
(Miltenyi Biotec). Cells were seeded in 24-well plates (1 ×
106 cells/well) and maintained in complete RPMI medium
(RPMI supplemented with 10% fetal bovine serum FBS, 1%
penicillin streptomycin, 2mM L-glutamine, and 50µM 2-
mercaptoethanol, all from Sigma-Aldrich) with 25 ng/mL rhIL-4
and 50 ng/ml rhGM-CSF (ImmunoTools) for 4 days followed
by replacement with fresh IL-4- and GM-CSF-supplemented
complete medium and cultivation for another 3 days.
Cell Lines
The mouse macrophage cell line J774.2 was cultured in complete
DMEM medium (DMEM supplemented with 10% fetal bovine
serum FBS, 1% penicillin-streptomycin, 2mM L-glutamine, and
50µM 2-mercaptoethanol, all from Sigma-Aldrich). Cells were
maintained in a humidified incubator at 37◦C and 5% CO2.
Isolation of Bone Marrow-Derived
Dendritic Cells (BMDCs)
Bone marrow-derived dendritic cells (BMDCs) were isolated as
described before (3, 44). Briefly, freshly isolated myeloid cells
were incubated in complete RMPI supplemented with 20 ng/mL
murine GM-CSF for 7 days. Non-adherent cells (including
lymphocytes and granulocytes) were removed at days 2 and
4 followed by adding fresh medium supplemented with GM-
CSF. Proportions of CD11c+ cells above 80% were routinely
obtained. The cells were maintained in complete RPMI medium
in a humidified incubator at 37◦C and 5% CO2.
Flow Cytometry of Human DCs
Cells were pre-incubated with human FcR Blocking Reagent
(Miltenyi Biotec) diluted 1:50 in flow cytometry buffer containing
0.5% BSA (Sigma-Aldrich) and 2mM EDTA in order to block
non-specific binding of immunoglobulins to the Fc receptors.
The cells were then stained with specific anti-human antibodies
for 20min at 4◦C and analyzed by flow cytometry using a
MACSQuant analyzer and the data were processed using FlowJo
software (FlowJo LLC).
Flow Cytometry of Mouse Cells
Cells were pre-incubated in PBS containing TruStain fcXTM
Fc Receptor Blocking Solution (BioLegend) diluted 1:500,
and eBioscienceTM Fixable Viability Dye eFluorTM 780
diluted 1:1000 in order to block non-spiecific binding
of immunoglobulins to the Fc receptors and exclude
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dead cells, respectively. Subsequently, cells were stained
with specific anti-mouse antibodies for 45min at 4◦C.
For intracellular staining of cytokines, the cells were
fixated in BD CytofixTM Fixation Buffer (BD Biosciences)
prior to staining and 0.5% saponin (Sigma-Aldrich) was
included in the flow cytometry buffer. After staining,
cells were analyzed on FACSCanto II flow cytometer (BD
Biosciences) and the data were analyzed and processed using
FlowJo software.
Activation of Antigen-Presenting Cells
(APCs)
Human DCs (1 × 106) were stimulated with L. plantarum
at a multiplicity of infection (MOI) of 200. A cocktail of
100 ng/ml LPS, 15 ng/ml TNF-α (ImmunoTools) and 5µM
PGE2 (Sigma-Aldrich) was included as a positive control. After
48 h incubation, the cells were detached with trypsin (Biowest)
and transferred to a V-bottom 96-well plate. Subsequently, the
human DCs were stained with specific anti-human antibodies for
cell surface molecules: VioBright FITC-conjugated CD40 diluted
1:50, PE-conjugated CD80 diluted 1:11, APC-conjugated CD86
diluted 1:11 and PE-conjugated HLA-DR diluted 1:11 (all from
Miltenyi Biotec).
Murine macrophages or DCs (2 × 105) were seeded in
triplicate in 96-well plates and allowed to adhere to the well
surface for 2–4 h in a humidified incubator at 37◦C and 5%
CO2. The cells were stimulated with recombinant L. plantarum
at an MOI of 100 or with 100 ng/mL LPS for 24 h or 48 h. The
cells were then stained with specific anti-mouse antibodies for
cell surface molecules: PerCP/Cy5.5-conjugated CCR7, Brilliant
Violet 510TM-conjugated MHC class II, FITC-conjugated MHC
class I, Brilliant Violet 421TM-conjugated PD-L1, PE-conjugated
PD-L2, APC-conjugated CD80 and PE/Cy7-conjugated CD86
(all from BioLegend), all diluted 1:150.
Cytokine Analysis
The pro-inflammatory cytokines were analyzed by ELISA in
culture supernatants from stimulated APCs. Murine IL-6, TNF-
α, IL-1β, and IFN-γ were measured by ELISA using eBioscience
Ready-Set-Go kits following the manufacturer’s instructions and
plates were read on a Tecan200 plate-reader. Human IL-6, TNF-
α, IL-1β, and IL-12 weremeasured using PeproTech ABTS ELISA
Development Kits following the manufacturer’s instructions and
plates were read on a Sunrise Plate Reader (Tecan). IL-12p40 was
detected by intracellular cytokine staining after 24 h stimulation
of murine APCs in the presence of 10µg/mL brefeldin A (Sigma-
Aldrich) using IL-12p40-PE (BioLegend) diluted 1:50.
Animals
Female C57BL/6mice at the age of 6–8 weeks were obtained from
Charles River, UK and were divided in 6 groups (n = 10). All
animals were used with approval from St. George’s University of
London Ethics Committee under an approved UK Home Office
animal project license and used in accordance with the Animals
(Scientific Procedures) Act 1986.
Vaccines
BCG, Lp_DC and Lp_HBD cultures were prepared as described
above. For Lp vaccines, the immunization dose consisted of 1
× 109 bacterial cells and 20 µg the adjuvant poly (I:C) (Sigma-
Aldrich) in sterile PBS. For BCG vaccine, the immunization
dose contained 5 × 105 CFU BCG Pasteur in sterile PBS. Mice
were administered with 100 µL and 50 µL for subcutaneous and
intranasal immunization, respectively. All intranasal inoculations
were performed under light anesthesia using isoflurane.
Immunization Protocol
Two prime-boost immunization regimens were applied to test Lp
vaccines efficacy: i) a heterologous regimen where Lp constructs
were tested as a booster to BCG vaccine, and ii) a homologous
FIGURE 2 | Immunization protocols. Two prime-boost immunization strategies were applied: a heterologous regimen including parenteral BCG immunization followed
by three intranasal Lp boosts (A), and a homologous regimen including parenteral Lp immunization followed by two intranasal boosts (B). Mice were challenged with
M. tuberculosis via aerosol delivery 3 weeks after the last vaccination. The experiment was terminated 4 weeks after mycobacterial infection.
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regimen where Lp constructs were used as a primary vaccine. The
schematic protocol is presented in Figure 2.
Heterologous Regimen (Figure 2A)
Mice were immunized subcutaneously with BCG followed
by intranasal boosting with Lp vaccines given in three
doses administered every 2 weeks, starting 8 weeks after the
BCG priming.
Homologous Regimen (Figure 2B)
Lactobacillus plantarum vaccines were given subcutaneously
followed by two intranasal applications given every 2 weeks
after priming.
Three weeks after the last immunization, three animals
from each group were sacrificed for immunogenicity analysis
and the remaining animals were used in a M. tuberculosis
challenge experiment.
Challenge With M. tuberculosis
Mice were infected with ∼200 M. tuberculosis bacilli per animal
delivered via low-dose aerosol, using a Biaera aerosol generator
(Biaera Technologies). Four weeks after the infection, the mice
were sacrificed and lungs and spleens were taken in order to
evaluate mycobacterial burden. The organs were homogenized
in a stomacher (Seward) containing 0.1% Triton X-100 and
the homogenates were plated in duplicates (lungs) or singlets
(spleens) on completed 7H11 agar and incubated at 37◦C for 3-4
weeks. Subsequently, CFU were counted.
Preparation of Tissues From Mice
Isolation of Splenocytes
The spleens were collected, mashed through 70µm Corning R©
cell strainers (Sigma-Aldrich) and centrifuged at 300 × g for
10min at room temperature. The cell pellets were resuspended
and incubated in Red Cell Lysis buffer (Sigma-Aldrich) for
5min, recovered by centrifugation and washed with RPMI 1640
medium. Cells were maintained in complete RPMI medium in a
humidified incubator at 37◦C and 5% CO2.
Serum Preparation
Blood collected from mice was allowed to clot at room
temperature for 1 h, followed by centrifugation at 1,000–2,000 ×
g for 10min at 4◦C. Serum was stored at−20◦C until analysis.
Bronchoalveolar Lavage (BAL)
Onemilliliter of sterile PBS was injected into the lungs via trachea
and following three rounds of flashing the washes were collected
and stored at−20◦C until analysis.
IgG and IgA Antibodies Assays
ELISA assays were used to determine antigen-specific titers for
IgG in serum and IgA in BAL. Microtiter plates were coated
with 5µg/ml Ag85B or ESAT-6 (both from Lionex GmbH) and
incubated overnight at room temperature followed by blocking
with 1% BSA (Sigma-Aldrich) in PBS for 1 h at 37◦C. Serial
dilutions of serum (10-fold) and BAL (3-fold) samples were
applied to the pre-coated plates followed by incubation for 1 h
at 37◦C. Subsequently, the plates were incubated for 1 h at 37◦C
with HRP-conjugated anti-mouse IgA or IgG antibodies (Sigma-
Aldrich), both diluted 1:1,000, for detection of IgA or IgG,
respectively. OPD Substrate Tablets (Sigma-Aldrich) were used
for color development, following the manufacturer’s instructions.
The OD at 450 nm was measured after 15min incubation at
room temperature.
T Cell Proliferation
Freshly isolated splenocytes (1 × 10E6) were seeded in 96-
well plates and stimulated with 5µg/mL Ag85B antigen
or 1 µ/mL ESAT-6 antigen. As positive control, the cells
were stimulated with 1µg/mL α-CD3 (BioLegends). Antigen-
specific T cell proliferation was analyzed after 6 days of
incubation with antigens. The cells were blocked, as described
above, and subsequently stained with PerCP/Cy5.5-conjugated
CD4, Brilliant Violet 510TM-conjugated CD8a, FITC-conjugated
CD44, PE-conjugated CD62L and Brilliant Violet 421TM-
conjugated CD90.2 antibodies (all from BioLegends), all
diluted 1:100. After staining, the cells were fixed using
eBioscienceTM Foxp3/Transcription Factor Staining Buffer Set
and permeabilized using eBioscienceTM Permeabilization Buffer,
according to the manufacturer’s instructions. Subsequently, cells
were intracellularly stained with 1:50 diluted APC-conjugated
Ki-67 antibody (BioLegends) and analyzed by flow cytometry.
T Cell Polyfunctionality
In order to analyze multifunctional antigen-specific T cells,
freshly isolated splenocytes (1.5 × 106) were seeded in 96-
well plates and stimulated with 5µg/mL Ag85B or 1 µ/mL
ESAT-6 antigens. As a positive control, cells were stimulated
with 100 ng/mL PMA and 1µg/mL Ionomycin. After 4 h
incubation, cells were blocked and fixed, as described in Flow
cytometry of mouse cells paragraph. Subsequently, cells were
stained with FITC-conjugated CD3, PerCP/Cy5.5-conjugated
CD4, Brilliant Violet 510TM-conjugated CD8a, APC-conjugated
TNF-α, PE/Cy7-conjugated IL-17A, PE/Cy5-conjugated IL-2 and
Brilliant Violet 421TM-conjugated IFN-γ antibodies (all from
BioLegends), all diluted 1:100, and analyzed by flow cytometry.
RESULTS
The Lp Constructs Display the AgE6
Antigen on the Bacterial Surface
The AgE6 hybrid antigen was displayed on the bacterial
surface through an N-terminal lipoprotein anchor derived from
Lp_1261, which ensured covalent biding of the antigen to the
bacterial cell membrane (25, 38). Two targeting peptides were
selected in order to target AgE6-producing bacteria to eukaryotic
cells and a schematic overview of the constructs is shown on
Figure 1. The Lp_DC construct was constructed as described
previously (25) so that the DC-targeting peptide was fused to
the C-terminal end of the AgE6 antigen (Figure 1A). In the
Lp_HBD construct, the HBD fragment from the HBHA surface
protein ofM. tuberculosis was fused to the C-terminal end of the
AgE6 antigen (Figure 1B) replacing the DC-targeting peptide.
HBD is a methylated lysine-rich C-terminal fragment of HBHA
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FIGURE 3 | Production (A) and surface localization (B,C) of the recombinant AgE6 antigen. Production of the anchor-fused AgE6 in Lp_DC and Lp_HBD constructs
was analyzed by Western blotting and is shown in (A). The positions of size marker proteins are indicated and predicted sizes of the detected proteins (Figure 1) are
48.4 and 54.1 kDa for Lp_DC and Lp_HBD constructs, respectively. The presence of AgE6 on the bacterial surface was detected using immunofluorescent methods:
flow cytometry and fluorescent microscopy. Lp_Ev was used as a negative control strain. Panel B shows flow cytometry analysis for Lp_DC and Lp_HBD (gray
histograms) and Lp_Ev (black histograms). Panel C shows indirect immunofluorescence microscopy of the indicated constructs. The data presented are from a
representative experiment. Each experiment was performed three times, giving similar results.
that mediates an interaction with epithelial and non-phagocytic
cells (45–47).
The expression of recombinant AgE6 antigens was evaluated
by Western blot analyses of cell-free crude protein extracts from
growing and induced L. plantarum constructs. Figure 3A shows
bands of the correct size for both Lp_DC (48.4 kDa) and Lp_HBD
(54.13 kDa), as well as some smaller protein fragments that are
likely degradation products, while no bands were detected in a
protein extract of the negative control strain (data not shown).
Flow cytometry of bacteria labeled with an anti-ESAT-6 antibody
showed drastically increased fluorescence intensity for both
antigen-producing constructs when compared to the negative
control strain, Lp_Ev (Figure 3B). Fluorescent microscopy gave
clear signals for bacteria expected to produce AgE6 but not for
Lp_Ev (Figure 3C).
The Lp Constructs Activate Human and
Mouse APCs
Activation of professional APCs, such as dendritic cells and
macrophages, is essential for post-immunization T cell priming
(3, 48). Conserved bacterial components, so called microbe-
or pathogen-associated molecular patterns (MAMPs or PAMPs,
respectively), can contribute to APCs activation reflecting
in expression of co-stimulatory molecules and secretion of
cytokines. We investigated the ability of the Lp_DC and Lp_HBD
vaccine candidates to activate human DCs and mouse DCs and
macrophages. The innate immune cells were stimulated with UV-
inactivated bacteria for 48 h and examined for upregulation of
co-stimulatory molecules and production of pro-inflammatory
cytokines (Figure 4).
The results for human DCs showed a tendency toward
upregulation of CD83, CD40, CD80, and HLA-DR molecules,
and showed elevated concentrations of secreted IL-6, IL-12, TNF-
α, IL-1β, after stimulation with both Lp constructs (Figure 4A).
Notably, the levels of measured cytokines were higher for Lp-
stimulated DCs, compared to LPS/TNF-α/PGE2 stimulation,
which was used as positive control, although the difference was
not statistically significant (Figure 4A).
The assessed expression of surface markers in murine DCs
revealed that Lp_HBD upregulated CD80 (p< 0.05) (Figure 4B).
For both Lp_DC and Lp_HBD a tendency toward upregulation of
PD-L1, MHC class I and, in lesser degree, CD86, was observed,
but differences were not statistically significant (Figure 4B).
None or very low upregulation was detected for CCR7, while
MHC class II and PD-L2 were downregulated (Figure 4B).
Quantification of secreted pro-inflammatory cytokines showed
high production of TNF-α (p < 0.05) in cells exposed to
Lp_DC or Lp_HBD and a tendency toward elevated IL-6
levels (Figure 4B).
For mouse macrophages, we detected significant upregulation
of MHC class I, MHC class II, PD-L1, PD-L2, and CCR7
upon exposure to each of the two Lp constructs and
tendencies toward up-regulation of CD80 and CD86. Cytokine
measurements revealed significantly increased concentrations of
TNF-α (p < 0.05 for Lp_HBD) and IL-6 (p < 0.05) as shown
in Figure 4C.
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FIGURE 4 | Activation of human DCs (A), mouse DCs (B), and mouse macrophages (C) by UV-inactivated lactobacilli. APCs were incubated with Lp_DC or Lp_HBD
at MOI of 200 for human cells and 100 for mouse cells, for 24 or 48 h. Expression of surface co-stimulatory molecules was measured by flow cytometry and the
median fluorescence intensity (MFI) was normalized to the unstimulated controls. Pro-inflammatory cytokines in culture supernatants were quantified by ELISA.
IL-12p40 in mouse APCs was detected by intracellular staining followed by flow cytometry and the plots are from a representative experiment of cells stimulated with
LPS (100 ng/mL), Lp_DC or Lp_HBD. For human DCs (A), three blood donors were tested and the data are shown as a mean ± SEM. The results for mouse cells
(B,C) are presented as a mean from three independent experiments and the data are shown as a mean ± SEM. Statistically significant differences were tested against
the unstimulated controls using paired t-test and are indicated as follows: *p < 0.05, **p < 0.01, and ***p < 0.001.
Production of IL-1β was not detected in the supernatants
from mouse APCs (data not shown). Analysis of intracellularly
produced and captured IL-12p40 in mouse immune
cells indicated positive responses to LPS, Lp_DC and
Lp_HBD (Figures 4B,C).
Thus, Lp_DC and Lp_HBD activated APCs and induced
multiple cytokine responses, but we did not observe
any significant differences between the two constructs in
in vitro assays.
Lp_DC and Lp_HBD Induce Moderate
Antibody Responses
We tested the Lp-based vaccine candidates in a mouse model
using two different immunization regimens as outlined in
Figure 2, and included non-immunized mice (naïve) and single
parenteral BCG immunization as controls. Three weeks after the
last vaccination, immune response were assessed.
In order to evaluate humoral responses, we measured the
titers of antigen-specific IgG in serum samples and IgA in lung
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washes, specific to Ag85B or ESAT-6 antigens. Analysis of serum
samples showed no significant elevation of anti-Ag85B IgG in
any of the groups but showed a tendency toward increased levels
of IgG against ESAT-6 upon heterologous immunization with
Lp_DC (Figure 5A). Studies of lung washes showed significantly
improved IgA titers for mice boosted with Lp_DC in the
heterologous regimen for both Ag85B and ESAT-6 and also
a noticeable increased anti-Ag85B IgA in mice that received
Lp_DC as a primary vaccine (Figure 5B). Lp_HBD induced
modest increase of IgA specific to both antigens in lung washes
only when given as a BCG boost (Figure 5B).
Taken together, the results suggest that Lp-based constructs
elicit merely low or moderate levels of antibody responses to the
antigens, both systemically and in the mucosa, and in general the
effects were better detectable for Lp_DC construct.
Lp_DC and Lp_HBD Enhance BCG-Induced
T Cell Proliferative Responses
In the next steps, we investigated the cellular immunity evoked
by the Lp-based vaccine candidates. First, we examined whether
immunization with Lp_DC or Lp_HBD induced antigen-
specific T cell proliferation in the spleen. To do so, we
examined expression of proliferation marker Ki67 in splenocytes
from immunized mice by incubating with recalling antigens
(Figure 6). Furthermore, using the CD44 and CD62L markers,
we discriminated between T cell phenotypes: T central (TCM;
CD44hiCD62Lhi), T effector (TEM; CD44
hiCD62Llo) memory
cells, and naïve T cells (TNaive CD44
loCD62Lhi) (Figure 6).
Among Ag85B-stimulated splenic CD4+ T cell populations,
we observed increased levels of Ki67+ cells in groups boosted
with Lp_DC (∼25%, for all three phenotypes together) or
Lp_HBD (∼19%) in the heterologous regimen, compared to non-
immunized mice (∼6%) and to the BCG only group (∼8%).
The populations of CD8+ T cells showed elevated numbers
of Ag85B-induced Ki67+ T cells in mice singly immunized
with BCG (∼20%) and high proliferative responses for groups
of BCG-primed mice that had been boosted with Lp_DC
(∼50% Ki67+) or Lp_HBD (∼56% Ki67+), compared to naïve
mice (∼9% Ki67+).
Stimulation with the ESAT-6 antigen revealed only marginally
elevated levels of proliferating CD4+ T cells in mice that had
received only BCG (∼9% Ki67+), but stronger responses in
mice given heterologous boosts with Lp_DC (∼21% Ki67+)
or Lp_HBD (∼12% Ki67+). Ki67+CD8+ populations were
increased for mice immunized singly with BCG (∼19%) and
boosted with Lp_DC (∼28%), but not with Lp_HBD (∼12%).
Of note, antigen specific T-cell proliferation was not detected
for mice subjected to the homologous regimen primarily
immunized with Lp-based vaccines. Thus, taken together, the
overall picture emerging from Figure 6 is that T cell proliferation
for mice immunized with BCG and mucosally boosted with
Lp_DC or Lp_HBD was considerably higher compared to
BCG alone or to the homologous prime-boost regimen. The
populations of proliferating CD4+ and CD8+ T cells were
dominated by the TEM phenotype, whereas proportion of the
TCM phenotype remained modest (Figure 6).
Lp_DC and Lp_HBD Induce
Antigen-Specific IFN-γ Secretion
IFN-γ is a Th1 response cytokine playing essential role
in protection against intracellular pathogens, such as
M. tuberculosis, and is generally used as a relevant marker
for testing the immunogenic potential of new tuberculosis
vaccine candidates (49, 50). We investigated specific IFN-γ
responses in proliferating splenic T cells and observed that both
Ag85B and ESAT-6 antigens induced IFN-γ secretion for mice
immunized with Lp_DC or Lp_HBD, in both regimes, indicating
immunogenicity of Lp-based vaccines (Figure 7). No increase
in IFN-γ concentrations were detected in cells from the BCG
control group (Figure 7).
Lp_DC and Lp_HBD Elevate the Frequency
of Multifunctional T Cells
Polyfunctional T cells producing multiple pro-inflammatory
cytokines, i.e., IFN-γ, TNF-α and IL-2, have been associated
with protective immunity against M. tuberculosis infections in
multiple human and animal studies (51). In this regard, we
analyzed quality of CD4+ and CD8+ T cells from vaccinated
mice in terms of IFN-γ, IL-2, TNF-α, and IL-17. We included
IL-17, since this cytokine plays an important role in promoting
immunity during M. tuberculosis infection (52, 53) and is
suggested to play a role in vaccine-induced immunity (54).
The results for splenocytes stimulated with Ag85B showed
that heterologous immunization led to markedly increased
levels of double- and triple-positive cytokine-producing CD4+
T cells in mice given the Lp_DC construct (Figure 8). When
applied in the homologous regimen, Lp_DC was able to induce
various combinations of double-positive cytokine-producing
CD4+ T cells (except IL-2+TNF-α), whereas no cells producing
three cytokines were determined. On the other hand, in the
homologous regimen, Lp_HBD generated some populations
of triple- (IFN-γ+IL-2+TNF-α+ and IFN-γ+IL-2+IL-17+) and
double-cytokine-positive CD4+ T cells (Figure 8). CD8+ T cells
producing more than one cytokine were predominantly an IL-
2+IL-17+ population in mice given Lp_DC and Lp_HBD in
both regimens.
Multi-positive T cells recalled by the ESAT-6 antigen were
detected to a much lesser degree and comprised some double-
positive CD4+ T cells in mice vaccinated with Lp_HBD
in the heterologous (IFN-γ+TNF-α+ and IL-17+TNF-α+) or
with Lp_DC in homologous regimen (IL-17+TNF-α+), as well
as CD8+ T cells in mice vaccinated with Lp_DC in the
heterologous regimen (IFN-γ+IL-2+, IFN-γ+IL-17+ and IL-
2+IL-17+) (Figure 8).
Heterologous Boosting With Lp Vaccines
Confers Reduction of M. tuberculosis
Infection in Lungs
We evaluated the protective efficacy of Lp-based vaccine
candidates in a pathogenic M. tuberculosis challenge mouse
model. Three weeks after the last immunization mice were
infected with aerosolized M. tuberculosis (Figure 2) and the
bacterial loads in spleens and lungs were determined 4 weeks
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FIGURE 5 | Humoral responses induced by Lp_DC and Lp_HBD. Serial dilutions of serum (10-fold) and BAL (3-fold) samples were subjected to ELISA in order to
determine antibodies specific to Ag85B or ESAT-6. The end-point titers were evaluated for serum IgG (A) and BAL IgA (B). Results are presented as a mean ± SEM (n
= 2–3). Statistically significant differences were determined using one-way ANOVA with Tukey’s post-hoc test and are indicated as follows: *p < 0.05, **p < 0.01, and
****p < 0.0001.
later. Two independent experiments were performed using the
identical immunization regimen and, since animals displayed
very similar bacterial loads in their lungs in both experiments for
the control (mean CFUlog10 ± SEM = 6.24 ± 0.07 and 6.17 ±
0.11; n= 7) and BCG-immunized (mean CFUlog10 ± SEM= 5.25
± 0.06 and 5.19 ± 0.16; n = 6-7) groups, we combined the data
to increase the statistical power of the assay.
As expected, parenteral BCG vaccination reduced the
mycobacterial burden in lungs and spleens in comparison to
naïve mice (Figure 9). Notably, heterologous immunization
with both Lp_DC and Lp_HBD induced statistically significant
reduction in M. tuberculosis CFU numbers in lungs, when
compared to the BCG control group (Figure 9A), indicating a
protective potential of the Lp constructs when used as a BCG
boost. When given as homologous vaccines, both Lp candidates
showed tendency to lower the mycobacterial burden in lung
tissue compared to naïve mice, although insignificantly and not
as much as BCG (Figure 9A).
The mycobacterial loads in spleens showed significant
reduction of the M. tuberculosis load for mice heterologously
boosted with Lp_DC compared to naïve mice, but there
were no significant improvements for the groups that were
heterologously boosted with Lp_DC or Lp_HBD in caparison
to BCG-vaccinated mice (Figure 9B). Mice that were not given
BCG, but only Lp_DC or Lp_HBD, displayed a trend for lower
mycobacterial loads in spleens similar to BCG. Nevertheless,
comparing to the control group, the differences were not
statistically significant due to large variations between the
individual animals (Figure 9B). Taken together the observations
from the pathogenic challenge study indicate that vaccination
with Lp-based constructs improved the protection afforded by
BCG in the lungs and may afford some protection in the lungs
and the spleens when used as a homologous vaccination regimen.
DICUSSION
TB still kills millions of people in low- and middle-income
countries and the necessity for emerging new vaccines that
protect against M. tuberculosis infections remains indisputable.
TB vaccine development follows two major strategies, both
aiming to ensure life-long protection in immunized children:
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FIGURE 6 | Antigen specific T cell proliferation. Splenocytes from immunized mice were stimulated with Ag85B or ESAT-6 for 6 days. T cell proliferation was analyzed
by Ki67 staining using a live→ single cells→ CD3+ → CD4+/CD8+ → Ki67+ gating strategy. Central memory T cells (TCM), effector memory T cells (TEM) and
naive T cells (TNaive) were determined using CD44 and CD62L staining. Results are presented as a mean ± SEM of technical duplicates and are derived from n = 2–3
pooled spleens per group.
FIGURE 7 | IFN-γ secretion induced by recall antigens in proliferating splenic T cells. Splenocytes from immunized mice were stimulated with Ag85B or ESAT-6 for 6
days and levels of IFN-γ were quantified by ELISA. Results are presented as a mean ± SEM of technical duplicates and are from pooled spleens (n = 2–3).
(i) supplement the existing BCG vaccine or (ii) replace BCG
by a novel vaccine (55). In the present study we tested two L.
plantarum-based vaccine candidates in both approaches, namely
as BCG booster or primary vaccines.
Based on previous observations suggesting the potential
of using L. plantarum for vaccine delivery (25, 43), Lp was
engineered for producing the Ag85B-ESAT-6 fusion antigen and
to target this antigen to the bacterial surface. The antigen was
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FIGURE 8 | Frequency of CD4+ and CD8+ T cells producing multiple pro-inflammatory cytokines. Splenocytes from immunized mice were stimulated with Ag85B or
ESAT-6 in technical duplicates for 4 h. Splenic T cells producing IFN-γ, IL-2, IL-17, and TNF-α cytokines were determined by intracellular staining using live→ single
cells→ CD3+ → CD4+/CD8+ → IFN-γ+/IL-2+/IL-17+/TNF-α+ gating strategy. Thus, the frequencies of single-, double-, and triple- positive CD4+ and CD8+ T
cells were determined. The data are presented from n = 2–3 pooled spleens per group.
FIGURE 9 | Mycobacterial loads in lungs (A) and spleens (B) of mice immunized with Lp vaccines. Mice were administered with Lp_DC or Lp_HBD in a heterologous
or a homologous immunization regimen, as shown in Figure 2. Three weeks after the last vaccination, mice were infected with M. tuberculosis and 4 weeks later
bacterial burdens were quantified in lungs and spleens. Results are presented as a cumulative data from two independent experiments and are shown as a mean ±
SEM (n = 12-14). Statistically significant differences were determined using one-way ANOVA with Tukey’s post-hoc test and are indicated as follows: *p < 0.05 and
****p < 0.0001.
C-terminally extended by a DC-binding peptide (40, 41) or
an HBD-domain (45–47), resulted in two vaccine constructs:
Lp_DC and Lp_HBD, respectively (Figure 1).
We had earlier shown that Lp_DC induced TB-specific
immune responses when given through mucosal routes (25).
The goal of the present study was to investigate the protective
efficacy of the Lp-based TB vaccine candidates and to analyze
specific parameters that might correlate with protection. The
Lp_HBD construct was generated because the HBHA adhesin
is a known important virulence factor of M. tuberculosis that
binds epithelial cells and plays a crucial role in extrapulmonary
dissemination of the pathogen (56–58). Figure 3 shows that this
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new antigen construct was successfully produced and target to
the bacterial surface.
Lactobacillus plantarum has been shown to activate innate
immune cells and skew the immune system toward Th1
responses (35, 36). Indeed, we found that human and mouse
APCs pulsed with Lp_DC or Lp_HBD expressed important
co-stimulatory molecules, such as CD80, CD40, CD86, and
MHC class I/II (Figure 4), which are indicative of maturation
processes that are essential for triggering secondary immune
responses and post-immunization T cell activation (3, 48, 59).
We observed down-regulation of MHC class II in Lp-stimulated
murine DCs cells (Figure 4B) and that phenomenon has been
observed before in studies with bone-marrow derived DCs (60).
We quantified expression of PD-L1 and PD-L2, because there is
evidence that these molecules regulate T cells function (61). Both
mouse macrophages and DCs expressed PD-L1 (Figures 4B,C),
while PD-L2 was expressed by macrophages but down-regulated
in DCs (Figure 4B). Although regulation of PD-L1 and PD-
L2 may differ (62), we cannot presently explain the observed
down-regulation in murine DCs. The expression of chemokine
receptor CCR7 may be crucial for migration of activated DCs
to lung-draining lymph nodes; however, CCR7 expression by
mouse DCs stimulated with Lp constructs was low (Figure 4B).
It is important to note that recent evidence has highlighted
that GM-CSF-generated BMDCs contain macrophages as well
as DCs (63). Therefore, we cannot exclude the possibility of
non-DCs responding to our vaccine constructs. Future work
will specifically explore the role of various DC and macrophage
subsets in the immunological mechanisms of vaccine efficacy.
Lp constructs were given to mice as an intranasal booster
to BCG or as a primary vaccine administered first parenterally
followed by intranasal boosts (Figure 2). Although protective,
BCG is considered a rather poor inducer of antibody or T
cells responses (3, 64) and that trend was also observed in this
study. We investigated humoral and cellular immune responses
induced by Lp_DC and Lp_HBD and further evaluated in
what degree the immunogenic determinants corresponded to
observed protective effects. Humoral immunity induced by Lp-
based vaccines was generally poor and was mainly manifested in
increased IgA levels in lungs of mice that had received Lp_DC
in heterologous regimen (Figure 5). It has been considered for
years that the contribution of humoral immunity in controlling
M. tuberculosis infections is limited. Nowadays however, there
is evidence indicating that antibody-mediated responses may
restrict pathogen dissemination and play a significant role in
protection (6, 65). In contrast, the prominence of cellular
immunity is widely recognized (6), and T cells are considered
as major determinants of protection against M. tuberculosis
infections. The heterologous vaccination regimen applied in the
current study led to increased levels of CD4+ and CD8+ T cells,
while this was not the case when using Lp constructs as primary
vaccines (Figure 6). Effective vaccine is intended to establish
long-lived population of memory T cells (66) and, notably, BCG
boost with both Lp_DC and Lp_HBD constructs generated levels
of memory cells among proliferative T cells, with the effector
memory cells (TEM) as the major populations (Figure 6), which
has been observed in previous studies (67, 68).
Another important parameter of TB vaccine potential is IFN-
γ production by T cells, since this cytokine is known to maintain
cellular Th1 responses and to activate macrophages controlling
intracellular pathogens such as M. tuberculosis (69, 70). We
measured elevated INF-γ secretion by splenic cells stimulated
with Ag85B and to a lesser extent ESAT-6, for all groups
vaccinated with Lp constructs and in both regimens (Figure 7).
Somewhat unexpectedly, INF-γ production by splenic T cells
from mice that had received Lp_DC or Lp_HBD as the primary
vaccine was not reflected in increased generation of memory T
cells (Figure 6). This discrepancy can be explained if one assumes
that T cells producing only INF-γ are restricted in becoming
memory cells and that, rather multifunctional T cells, expressing
a combination of IFN- γ, IL-2 and TNF-α, are more prone to
become memory cells (66, 71). This assumption was supported
by the work of Aagaard et al., who demonstrated that increases
in double- (TNF-α and IL-2) or triple-positive (IFN-γ, IL-2 and
TNF-α) CD4+ T cells correlated with protection offered by TB
vaccine candidates in a mouse model (72). While we detected
clear increases in Ag85B-recalled double- and triple- positive
CD4+ T cells from mice immunized with Lp constructs in the
heterologous regimen, these increases were much less prominent
for groups given Lp as a primary vaccine (Figure 8), in seeming
accordance with lower levels of memory T cells. It should be
noted though that, although the role of multifunctional CD4+ in
protective immunity has been emphasized in numerous studies,
more recent evidence indicates that polyfunctional CD4+ T cells
might be insufficient or even non-associated with protection in
TB vaccine development (51).
While the multifunctional CD4+ T cells are widely studied,
an impact of multifunctional CD8+ T cells in protective
immunity remains little discussed in literature. Nonetheless,
multifunctional CD8+ T cells (IFN-γ, TNF-α, and IL-2) have
been linked to reduced risk of reactivation and enhanced control
of active TB in humans (73). In our study, immunization with
Lp_DC or Lp_HBD did not induce any triple-positive CD8+
T cell phenotypes and only low frequencies of a few double-
functional T cells (Figure 8).
Vaccine-induced IL-17 production in lungs has been shown
to be crucial for induction of T cell chemokines and recruitment
of CD4+ T cells after aerosol M. tuberculosis challenge
(74). Interestingly, we detected an elevated fraction of IL-17-
producing CD4+ T cells specific to mycobacterial antigens in all
groups given Lp, but not in the BCG control group (Figure 8).
This finding further supports the beneficial effect of using Lp-
based TB vaccines rather than BCG alone, which was also
reflected in increased protection in lungs when the heterologous
regimen was applied.
The most important finding of this study is that intranasally
administered Lp_DC and Lp_HBD enhanced the protection
provided by BCG in terms of reduced M. tuberculosis CFU
in lungs. When used as primary vaccines, the Lp constructs
tended to reduce bacterial load in lungs (comparing to non-
immunized mice), but effects were insignificant and not as good
as for BCG. One possible explanation for the lesser efficiency
of the homologous regimen can be the superior immunogenic
and antigenic nature of BCG over Lp. BCG is an attenuated
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pathogenic bacterium, rich in strong mycobacterial antigens and
PAMPs, while Lp constructs remain non-pathogenic bacteria
expressing two antigens ofM. tuberculosis. It cannot be excluded
that better results may be obtained when using Lp vaccines in a
homologous regimen, for example by optimizing the numbers
of administered Lp cells. The CFU data for spleens did show
lower CFU numbers in all vaccinated groups in relation to naïve
mice, but did not show statistically significant effects of the Lp
constructs in comparison to BCG-vaccinated mice. It is therefore
possible that the protective effect of the Lp constructs is smaller
once the pathogen has disseminated from lungs.
The measured protective immunity in lungs correlated with
cellular responses (i.e., proliferative responses, high IFN-γ levels
and high frequency of polyfunctional T cells), as well as the
modest elevation of lung IgA, induced by Lp_DC and Lp_HBD
in the heterologous regimen.
We used a DC-targeting peptide because our own
unpublished results had shown that this is beneficial for
immunogenicity and because the peptide was proven as an
essential element of an oral vaccine against anthrax (41).
The present data show that the two investigated constructs,
Lp_DC and Lp_HBD, are quite similar in terms of potential for
protection, and the ability to activate APCs and evoke cellular
immunity. It would be of interest to further investigate the
importance and the (possible) functional differences of the two
targeting sequences (DC-targeting peptide and HBD) exploited
in this study.
Lactobacillus plantarum has been presented as a potential
candidate for mucosal vaccine against tuberculosis that induced
a favorable immunogenic profile previously (25, 75). Yet, to
our knowledge, increased protection against M. tuberculosis
infection evoked by an engineered Lactobacillus has not been
reported before.
Taken together, this study shows that, when used as an
intranasal booster vaccine, two Lp-based constructs, Lp_DC and
Lp_HBD, triggered diverse components of immune system and
enhanced protection conferred by BCG. Primary immunization
with the Lp vaccine candidates induced some protective
immunity, but the effects were not as robust as for single
parenteral BCG vaccination. Thus, Lp_DC and Lp_HBD have
potential as a mucosal booster vaccine to BCG and merit further
development as a novel TB vaccine platform.
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